On July 14, Dong-A ST announced that the European Medicines Agency accepted its Marketing Authorization Application (MAA) for DMB-3115, a biosimilar referencing STELARA (ustekinumab). STELARA is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The MAA submission was based on the results of a phase III study in which DMB-3115 demonstrated therapeutic equivalence to STELARA in patients with plaque psoriasis.
Dong-A ST and Meiji Seika Pharma worked together to develop DMB-3115, and the worldwide distribution rights, excluding certain Asian regions, were licensed to Intas Pharmaceuticals. Intas Pharmaceuticals’ subsidiary Accord Healthcare will commercialize the product in the EU, UK, and Canada.
The post EMA Accepts MAA for Dong-A ST’s Ustekinumab Biosimilar appeared first on Big Molecule Watch.